Catalog No.
DHA05901
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-nd
Clonality
Monoclonal
Target
TNF-related apoptosis-inducing ligand receptor 1, APO2, Death receptor 4, TRAIL receptor 1, TRAIL-R1, CD261, DR4, TRAILR1, TNFRSF10A, Tumor necrosis factor receptor superfamily member 10A
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O00220
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
HGS-ETR1, TRM-1, CAS: 658052-09-6
Clone ID
Mapatumumab
111 In-Labeled mapatumumab, PMID: 20641403
99m Tc-Labeled mapatumumab, PMID: 20641397
Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1, PMID: 19243282
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study, PMID: 19652058
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib, PMID: 19174554
Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells, PMID: 25483927
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study, PMID: 19690193
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma, PMID: 21081929
Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer, PMID: 24560012
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma, PMID: 26802147
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer, PMID: 20068564
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies, PMID: 18519776
Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer, PMID: 18255187
Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda, PMID: 16248286
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1, PMID: 17416859
Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin, PMID: 17953743
Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis, PMID: 19788693
Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib, PMID: 26405606
Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20, PMID: 17671142
The role of Bcl-xL in synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia on human colon cancer, PMID: 23051936
Hyperthermia-enhanced TRAIL- and mapatumumab-induced apoptotic death is mediated through mitochondria in human colon cancer cells, PMID: 22174016
Hyperthermia enhances mapatumumab-induced apoptotic death through ubiquitin-mediated degradation of cellular FLIP(long) in human colon cancer cells, PMID: 23559011
Combination of the pro-apoptotic TRAIL-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions, PMID: 19695436
Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program, PMID: 19856388
99m Tc-Labeled lexatumumab, PMID: 20641185
111 In-Labeled lexatumumab, PMID: 20641892
Enhancement of death receptor 4-mediated apoptosis and cytotoxicity in renal cell carcinoma cells by anisomycin, PMID: 27879498
Evidence for two modes of synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia in human colon cancer cells, PMID: 24013390
TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors, PMID: 20940278
[Molecular targets in colon cancer], PMID: 16689454
Translating TRAIL-receptor targeting agents to the clinic, PMID: 22531313
Restoring TRAIL mediated signaling in ovarian cancer cells, PMID: 25030086
TRAIL-based therapeutic approaches for the treatment of pediatric malignancies, PMID: 23458616
Human monoclonal antibodies in cancer therapy: a review of recent developments, PMID: 23276961
Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells, PMID: 22738917
Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies, PMID: 22014269
Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma, PMID: 23029050
Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells, PMID: 30947287
Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer, PMID: 21653692
Gateways to clinical trials, PMID: 17440629
Gateways to clinical trials, PMID: 16395422
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma, PMID: 17335294
Gateways to clinical trials, PMID: 16810345
Gateways to clinical trials, PMID: 16845450
Gateways to clinical trials, PMID: 19088949
Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors, PMID: 20126991
Gateways to clinical trials, PMID: 20664824
TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5, PMID: 20354842
The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials, PMID: 33791337
RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex, PMID: 22890322
For research use only. Not for human or drug use.
